Company

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion
Eli LillyFinanical Reports

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Eli Lilly and Company (NYSE: LLY) reported third‑quarter 2026 worldwide revenue of USD 24.4 billion, up 39% year‑on‑year, driven by strong demand for its diabetes and obesity treatments Mounjaro (tirzepatide)…

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Biogen's Zurzuvae Receives Positive CHMP Opinion for Postpartum Depression Treatment
BiogenMarket approval filings

Biogen’s Zurzuvae Receives Positive CHMP Opinion for Postpartum Depression Treatment

Sanofi's Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma
CancerNASDAQ: SNY

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials
FinanceVelaVigo

Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials

Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases
Matchpoint TherapeuticsNovartis

Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases

Show More